Overview

ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)

Status:
Completed

Trial end date:
2021-03-19

Target enrollment:

Participant gender:

Summary

An open-label, single arm phase II study of the candidate Ebola Vaccine Ad26.ZEBOV/MVA-BN®-Filo

Phase:

Phase 2

Details

Lead Sponsor:

MRC/UVRI and LSHTM Uganda Research Unit
MRC/UVRI Uganda Research Unit on Aids

Collaborators:

Coalition for Epidemic Preparedness Innovations
Epicentre, Mbarara, Uganda
Epicentre, Paris, France and Mbarara, Uganda
Epicentre, Paris, France.
Janssen Pharmaceutica N.V., Belgium